Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7196726 | 0.93 | SLC6A3 (0.64) | MAOAMAOBTAAR1SLC6A4SLC6A3 | |
| SCHEMBL3517422 | 0.91 | SLC6A3 (0.67) | SLC6A4SLC6A3SLC6A2DPP4 | |
| Water SCHEMBL7265593 | 0.91 | SLC6A3 (0.62) | MAOAMAOBTAAR1SLC6A4SLC6A3 | |
| SCHEMBL2702974 | 0.88 | ICMT (0.53) | MAOAMAOBTAAR1SLC6A4SLC6A3 | |
| SCHEMBL2703418 | 0.88 | SLC6A3 (0.48) | MAOAMAOBTAAR1SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL29428962 | 0.87 | ICMT (0.52) | MAOAMAOBTAAR1SLC6A4SLC6A3 | |
| SCHEMBL4657320 | 0.85 | SLC6A4 (0.48) | MAOAMAOBTAAR1SLC6A4SLC6A3 | |
| SCHEMBL30824546 | 0.84 | HTR2A (0.46) | MAOAMAOBTAAR1SLC6A4SLC6A3 | |
| SCHEMBL27143071 | 0.84 | HTR2A (0.46) | MAOAMAOBTAAR1SLC6A4SLC6A3 | |
| SCHEMBL2701551 | 0.82 | SLC6A4 (0.43) | MAOAMAOBTAAR1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3510032-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORP (US) | 2022-07-06 | — | — | EP | claimed |
| EP-3510032-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | Incyte Corporation (US) | 2019-07-17 | — | — | EP | claimed |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | claimed |
| WO-2018049200-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | claimed |
| EP-4330236-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022232632-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-10934288-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200087301-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-03-19 | — | — | US | disclosed |
| US-10435405-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2019-10-08 | — | — | US | disclosed |
| US-10266530-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-20190106419-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-04-11 | — | — | US | disclosed |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| WO-2018049200-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
| EP-2114158-B1 | 3-SUBSTITUTED-[1,2,3]BENZOTRIAZINONE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMA INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| EP-2114158-A1 | 3-SUBSTITUTED-[1,2,3]BENZOTRIAZINONE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008085505-A1 | 3-SUBSTITUTED-[1,2,3]BENZOTRIAZINONE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087301-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | MAOA 2022/4885MAOB 1918/4885TAAR1 4739/4885 |
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | GRIN1, GRIN3B, GABRE | MAOA 452/4885MAOB 418/4885TAAR1 170/4885 |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | MAOA 2022/4885MAOB 1918/4885TAAR1 4739/4885 |
| US-10934288-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | MAOA 2022/4885MAOB 1918/4885TAAR1 4739/4885 |
| US-10435405-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | MAOA 2022/4885MAOB 1918/4885TAAR1 4739/4885 |
| US-20190106419-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | MAOA 2022/4885MAOB 1918/4885TAAR1 4739/4885 |
| US-10266530-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | MAOA 2022/4885MAOB 1918/4885TAAR1 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.